We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Steroid-Dopamine Combination May Be Fatal in Septic Shock

By HospiMedica International staff writers
Posted on 09 Feb 2011
A new study has found that a combination of steroids and dopamine is associated with an increased 28-day mortality in patients with shock, and in particular those with septic shock.

Researchers at Erasme University Hospital (Brussels, Belgium) performed a secondary analysis of the Sepsis Occurrence in Acutely Ill Patients (SOAP) trial, which was undertaken to determine whether dopamine or norepinephrine were superior as first-line vasopressor agents in restoring and maintaining blood pressure for the treatment of shock. More...
The trial assigned 858 patients with shock to receive dopamine and 821 patients to receive norepinephrine. In the original study, dopamine was associated with a nonsignificant increase in 28-day mortality, compared with norepinephrine; dopamine was also associated with significantly more arrhythmic events.

In search of confounding factors, the researchers went back and looked at the information on prednisolone and hydrocortisone use within 24 hours of randomization to dopamine or norepinephrine; steroid use was not randomized and was left to the discretion of the attending physician. In total, 885 (53.2%) of the SOAP patients received steroids, the most common of which was hydrocortisone (670 patients). The reanalysis found that overall, 28-day mortality tended to be higher in patients receiving steroids than in those not receiving steroids. The 28-day mortality rate was significantly higher in patients receiving steroids plus dopamine than in those receiving steroids plus norepinephrine, although it was similar in patients receiving dopamine or norepinephrine without steroids. The study was presented at the Society of Critical Care Medicine 40th critical care congress, held during January 2011 in San Diego (CA, USA).

"Dopamine should not be used anymore as a vasopressor; period. At least that's my opinion,” said lead author and study presenter Prof. Daniel De Backer, MD, of the department of intensive care. "You have more side effects and you face an increase in mortality rates, so it is of no benefit and is potentially more disadvantageous [and therefore] probably not a good idea to use it.”

Norepinephrine acts mainly in the locus coeruleus area of the brainstem. When released, it has an impact on the "fight-or-flight" response, the body's biological response to stress. In addition, norepinephrine is also involved in pain, cognition, mood, emotions, movement, and blood pressure.

Related Links:
Erasme University Hospital


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.